Literature DB >> 24652705

Nuclear factor kappa B inhibition improves conductance artery function in type 2 diabetic mice.

Modar Kassan1, Soo-Kyoung Choi, Maria Galán, Mohamed Trebak, Souad Belmadani, Khalid Matrougui.   

Abstract

BACKGROUND: We previously reported that enhanced nuclear factor kappa B (NFκB) activity is responsible for resistance arteries dysfunction in type 2 diabetic mice.
METHODS: In this study, we aimed to determine whether augmented NFκB activity also impairs conductance artery (thoracic aorta) function in type 2 diabetic mice. We treated type 2 diabetic (db(-) /db(-) ) and control (db(-) /db(+) ) mice with two NFκB inhibitors (dehydroxymethylepoxyquinomicin, 6 mg/kg, twice a week and IKK-NBD peptide, 500 µg/kg/day) for 4 weeks.
RESULTS: As expected, the NFκB inhibition did not affect blood glucose level and body weight. Thoracic aorta vascular endothelium-dependent relaxation (EDR), determined by the wire myograph, was impaired in diabetic mice compared with control and was significantly improved after NFκB inhibition. Interestingly, thoracic EDR was also rescued in db(-) /db(-p50NFκB-/-) and db(-) /db(-PARP-1-/-) double knockout mice compared with db(-) /db(-) mice. Similarly, the acute in vitro down regulation of NFκB-p65 using p65 shRNA lentiviral particles in arteries from db(-) /db(-) mice also improved thoracic aorta EDR. Western blot analysis showed that the p65NFκB phosphorylation, cleaved PARP-1 and COX-2 expression were increased in thoracic aorta from diabetic mice, which were restored after NFκB inhibition and in db(-) /db(-p-50NFκB-/-) and db(-) /db(-PARP-1-/-) mice.
CONCLUSIONS: The present results indicate that in male type 2 diabetic mice, the augmented NFκB activity also impairs conductance artery function through PARP-1 and COX-2-dependent mechanisms.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  COX-2; NFκB; PARP-1; endothelial function; thoracic aorta; type 2 diabetes

Mesh:

Substances:

Year:  2015        PMID: 24652705      PMCID: PMC4829069          DOI: 10.1002/dmrr.2542

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  38 in total

Review 1.  Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I.

Authors:  Mark A Creager; Thomas F Lüscher; Francesco Cosentino; Joshua A Beckman
Journal:  Circulation       Date:  2003-09-23       Impact factor: 29.690

2.  Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes.

Authors:  Andrea Natali; Elena Toschi; Stephanie Baldeweg; Demetrio Ciociaro; Stefania Favilla; Luigi Saccà; Ele Ferrannini
Journal:  Diabetes       Date:  2006-04       Impact factor: 9.461

3.  Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase.

Authors:  F G Soriano; P Pacher; J Mabley; L Liaudet; C Szabó
Journal:  Circ Res       Date:  2001-10-12       Impact factor: 17.367

4.  The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes.

Authors:  Pal Pacher; Lucas Liaudet; Francisco Garcia Soriano; Jon G Mabley; Eva Szabó; Csaba Szabó
Journal:  Diabetes       Date:  2002-02       Impact factor: 9.461

5.  Type 2 diabetic mice have increased arteriolar tone and blood pressure: enhanced release of COX-2-derived constrictor prostaglandins.

Authors:  Zsolt Bagi; Nora Erdei; Attila Toth; Wei Li; Thomas H Hintze; Akos Koller; Gabor Kaley
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-06-09       Impact factor: 8.311

6.  Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes.

Authors:  S P Laing; A J Swerdlow; S D Slater; A C Burden; A Morris; N R Waugh; W Gatling; P J Bingley; C C Patterson
Journal:  Diabetologia       Date:  2003-05-28       Impact factor: 10.122

7.  Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice.

Authors:  Jun Su; Pamela A Lucchesi; Romer A Gonzalez-Villalobos; Desiree I Palen; Bashir M Rezk; Yasuhiro Suzuki; Hamid A Boulares; Khalid Matrougui
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-05-15       Impact factor: 8.311

8.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

Authors:  S M Haffner; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

9.  Molecular mechanisms of high glucose-induced cyclooxygenase-2 expression in monocytes.

Authors:  Narkunaraja Shanmugam; Irene T Gaw Gonzalo; Rama Natarajan
Journal:  Diabetes       Date:  2004-03       Impact factor: 9.461

10.  Vascular dysfunction in experimental diabetes is improved by pentaerithrityl tetranitrate but not isosorbide-5-mononitrate therapy.

Authors:  Swenja Schuhmacher; Matthias Oelze; Franziska Bollmann; Hartmut Kleinert; Christian Otto; Tjebo Heeren; Sebastian Steven; Michael Hausding; Maike Knorr; Andrea Pautz; Kurt Reifenberg; Eberhard Schulz; Tommaso Gori; Philip Wenzel; Thomas Münzel; Andreas Daiber
Journal:  Diabetes       Date:  2011-08-15       Impact factor: 9.461

View more
  1 in total

1.  Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnostics.

Authors:  Etheresia Pretorius; Janette Bester; Natasha Vermeulen; Sajee Alummoottil; Prashilla Soma; Antoinette V Buys; Douglas B Kell
Journal:  Cardiovasc Diabetol       Date:  2015-03-08       Impact factor: 9.951

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.